Effect of a very late antigen‐4 receptor antagonist on allergen‐induced airway responses and inflammation in asthma

@article{Diamant2005EffectOA,
  title={Effect of a very late antigen‐4 receptor antagonist on allergen‐induced airway responses and inflammation in asthma},
  author={Zuzana Diamant and Julianna Kuperus and Robert A. Baan and K Nietzmann and Sylvaine Millet and Paola Assunç{\~a}o Mendes and Barry Miller and Dilip Amin and Shashank Rohatagi and Peter J. Sterk and H C Hoogsteden and Jan-Bas Prins},
  journal={Clinical \& Experimental Allergy},
  year={2005},
  volume={35}
}
Background Very late antigen‐4 (VLA4) plays a key role in the recruitment of eosinophils in allergic responses in animal studies. 
View on Wiley
ncbi.nlm.nih.gov
29 Citations
Background Citations
8
Methods Citations
2
Results Citations
2

29 Citations

Citation Type

Citation Type

The effect of a single inhaled dose of a VLA‐4 antagonist on allergen‐induced airway responses and airway inflammation in patients with asthma
TLDR
It is suggested that VLA‐4 may not play a major role in allergen‐induced airway responses and inflammation in asthma.
Non-invasive sampling methods of inflammatory biomarkers in asthma and allergic rhinitis
In this thesis, a series of clinical studies have been described, in which we applied, evaluated or modified novel and existing non- or semi-invasive sampling methods and detection techniques for the…
Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma.
TLDR
Despite its demonstrated pharmacologic activity against inhaled NKA, multiple doses of AVE5883 increased the allergen-induced airway responses without affecting markers of airway hyperresponsiveness and airway inflammation.
Original article: Nasal nitric oxide: longitudinal reproducibility and the effects of a nasal allergen challenge in patients with allergic rhinitis
TLDR
Exhaled nitric oxide (eNO) is a validated noninvasive marker of airway inflammation in asthma and in patients with allergic rhinitis (AR) and the applicability of nNO as a marker of upperAirway inflammation awaits validation.
Strategies for targeting T-cells in allergic diseases and asthma.
Very late antigen-4 integrin antagonists
TLDR
The present review summarizes work establishing natalizumab as an agent for the treatment of multiple sclerosis and Crohn's disease as well as the safety concerns caused by the development of progressive multifocal leukoencephalopathy in three patients during natalIZumab trials.
A critical appraisal of methods used in early clinical development of novel drugs for the treatment of asthma.
Inhaled allergen bronchoprovocation tests.
Up‐regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid
TLDR
The data link the up‐regulation of the eosinophil chemotactic factor CCL26 in BP to the lesional accumulation of activated eOSinophils in the skin, which broaden the understanding of BP pathogenesis and might indicate new options for therapeutic intervention.
The rabbit as a model to study asthma and other lung diseases.
  • S. Keir, C. Page
  • Biology, Medicine
    Pulmonary pharmacology & therapeutics
  • 2008
...
...

References

SHOWING 1-10 OF 30 REFERENCES
Blockade of late-phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4.
TLDR
It is demonstrated that a small-molecule VLA-4 inhibitor, when given by aerosol, has a protective effect against antigen-induced late responses and airway hyperresponsiveness in allergic sheep.
Mechanisms regulating eosinophil extravasation in asthma.
  • E. Knol, D. Roos
  • Biology, Medicine
    The European respiratory journal. Supplement
  • 1996
TLDR
Activating cytokines, such as interleukin (IL)-5, regulated upon activation in normal T-cells (RANTES) and monocyte chemotactic peptide (MCP)-3 specifically act on eosinophils, which induce a specific infiltration into tissue allergic inflammation.
The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.
Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents.
A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation.
TLDR
After intranasal treatment with compound A, eosinophils in the lungs and their activation products were substantially decreased, documenting its effectiveness in inhibiting lung inflammation.
The effect of anti-integrin monoclonal antibodies on antigen-induced pulmonary inflammation in allergic rabbits.
Reproducibility of allergen-induced early and late asthmatic responses.
Allergen‐induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation
TLDR
It is proposed that fluctuations in CCR3 expression on human BM CD34+ cells may facilitate chemokine‐mediated progenitor cell mobilization to the peripheral circulation and the resultant development of pulmonary eosinophilia, a cardinal feature of asthma.
Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation.
TLDR
The results suggest that the effects of inhaled glucocorticosteroids on allergen-induced airway responses may be mediated through their inhibition of allergenic-induced eosinophil migration and activation.
Alpha 4 integrin antagonists.
TLDR
The rationale for targeting alpha4 integrins for the treatment of autoimmune disorders is discussed and the methods used to identify lead molecules and the progress of selected antagonists toward becoming new drugs will be discussed.
...
...